Revvity Q3 2025 Financial Results

Revvity, Inc. announced its financial results for the third quarter ended September 28, 2025. The company reported revenue of $699 million, representing a 2% reported growth and 1% organic growth. GAAP earnings per share (EPS) were $0.40, while adjusted EPS from continuing operations was $1.18. The company reaffirmed its full-year 2025 organic growth guidance and raised its adjusted EPS guidance to a range of $4.90 to $5.00. Additionally, Revvity's Board of Directors authorized a new $1 billion share repurchase program. The Life Sciences segment reported revenue of $343 million, while the Diagnostics segment reported revenue of $356 million. The company also highlighted its strategic partnerships and innovations, positioning it for future success.